Clinical Trial Update: A Study to Assess the Long-term Safety of QVA149 [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of QVA149 (indacaterol/glycopyrronium) in chronic obstructive pulmonary disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium) (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-01-21